<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01093651</url>
  </required_header>
  <id_info>
    <org_study_id>KEY03222010</org_study_id>
    <nct_id>NCT01093651</nct_id>
  </id_info>
  <brief_title>Dipeptidyl Peptidase-4 Inhibition and Immune Function in HIV</brief_title>
  <acronym>DPPIVinHIV</acronym>
  <official_title>A Blinded Randomized Controlled Pilot Immunologic and Virologic Safety Trial of an FDA-approved DPPIV-inhibitor in HIV+ Men and Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Campbell Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We will test the safety of a new class of anti-diabetes compounds (DPPIV-inhibitors) in
      people living with HIV. Future trials will examine efficacy for treating diabetes and
      reducing cardiovascular disease risk in people living with HIV.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Human immunodeficiency virus (HIV)-infection and treatment with antiretroviral therapies are
      associated with several cardiometabolic risk factors; insulin resistance, diabetes,
      dyslipidemia, central adiposity, that increase risk for MI and stroke. A new class of drugs
      used to treat type 2 diabetes has been introduced; Dipeptidyl peptidase-IV (DPPIV)-inhibitors
      (Januvia®, Onglyza®, alogliptin). Dipeptidyl peptidase-IV (DPPIV)-inhibition could be a safe
      and effective therapy for HIV-associated insulin resistance and diabetes. However, no safety
      data exist. The research question is: If HIV+ adults with stable immunologic (CD4+ T-cell
      count &gt;350 cells/μL) and virologic (plasma HIV RNA &lt;50 copies/mL) function are given a
      DPPIV-inhibitor would their CD4+ T-cell count and plasma HIV RNA level increase, decrease, or
      stay the same? Theoretically, DPPIV-inhibition could enhance their immune system by
      increasing SDF-1α levels; a potent inhibitor of HIV-entry into T-cells, or harm the HIV+
      immune system by inactivating CD26 on immune cells. We hypothesize that DPPIV-inhibition will
      not harm the immune system in HIV+ people. We propose a blinded randomized controlled pilot
      safety trial of an FDA-approved DPPIV-inhibitor in virologically- and immunologically-stable
      HIV+ men and women. We will monitor CD4+ T-cell count, plasma HIV RNA levels, immune
      activation markers, and safety outcomes (lipid/lipoprotein profiles, blood pressure, kidney
      and liver function) during 4-6 months of DPPIV-inhibitor exposure vs placebo in 20 HIV+
      adults. If safety is confirmed, the efficacy of DPPIV-inhibition in HIV+ with insulin
      resistance will be tested in future trials that examine potential glucoregulatory and
      cardiovascular benefits.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CD4+ T-cell Count</measure>
    <time_frame>Monthly for 4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma HIV Viremia (Viral Load)</measure>
    <time_frame>Monthly for 6 months</time_frame>
    <description>Percentage of participants with plasma HIV RNA copy number less than 48 copies/mL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Soluble TNFR2; Serum Biomarkers of Immune Activation</measure>
    <time_frame>Baseline, week 8, week 16</time_frame>
    <description>serum soluble tumor necrosis factor receptor-2 concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SDF1α; Serum Biomarkers of Immune Activation</measure>
    <time_frame>Baseline, week 8, week 16</time_frame>
    <description>serum stromal cell-derived factor-1α concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RANTES; Serum Biomarkers of Immune Activation</measure>
    <time_frame>Baseline, week 8, week 16</time_frame>
    <description>serum Regulated on Activation, Normal T cell Expressed and Secreted concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral Glucose Tolerance</measure>
    <time_frame>Baseline, week 8, week 16</time_frame>
    <description>Area under the 75-gr oral glucose tolerance curve (AUCg) based on plasma glucose values measured at 0, 30, 60, 90, and 120 mins post-glucose challenge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-reported Symptoms</measure>
    <time_frame>Monthly for 4 months</time_frame>
    <description>Cumulative number of self-reported symptoms based on the Division of AIDS Grading Scale for the Severity of Adult Adverse Events (0-4 scale where 0 is no new symptoms, 4 is serious adverse event or toxicity)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Diabetes</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>DPPIV inhibition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four to six months of sitagliptin administration (100mg/d) to people living with HIV-1 who have well-controlled immunologic (CD4+ T-cell count &gt;350 cells/µL) and virologic (plasma HIV RNA &lt;50 copies/mL) status.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Four to six months of placebo to people living with HIV-1 who have well-controlled immunologic (CD4+ T-cell count &gt;350 cells/µL) and virologic (plasma HIV RNA &lt;50 copies/mL) status.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>100 mg sitagliptin daily for 4-6 months</description>
    <arm_group_label>DPPIV inhibition</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Daily placebo for 4-6 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Thirty 18-65 yr old HIV-infected men and women (with source documentation of HIV
             status) who are stable on any antiretroviral therapy (cART) regimen

          2. Have stable (at least the past 12-months) immunologic (&gt;350 CD4+ T-cells/µL) and
             virologic (&lt;50 copies HIV RNA/mL) status.

          3. BMI 18-42kg/m2;

          4. Normal blood chemistry for at least 1 month prior to enrollment;

          5. Platelet count &gt; 30,000/mm3, absolute neutrophil count &gt;750/mm3, transaminases &lt; 2.5x
             the upper limit of normal (ULN).

          6. Long-term non-progressors (not on ART) are not eligible.

        Exclusion Criteria:

          1. CD4+ T-cell count &lt;350 cells/µL or detectable plasma HIV RNA (&gt;50 copies HIV RNA/mL)
             within the past 12-months. During the study, if CD4+ T-cell count declines by &gt;100
             cells/µL, or if plasma HIV RNA becomes detectable (&gt;50 copies HIV RNA/mL after repeat
             analysis 2wks apart), and the participant denies any lapse in their anti-HIV
             medication regimen, the study medication will be stopped and an adverse event
             documented. If at any time during the study, two participants experience a reduction
             in T-cell count &gt;100 cells/µL, or their plasma HIV RNA levels become detectable (&gt;50
             copies HIV RNA/mL after repeat analysis 2wks apart), and they are confirmed (by
             unblinding) to have received sitagliptin, the study will be stopped for serious safety
             concerns.

          2. Systemic, secondary or opportunistic infection within past 12-months.

          3. Fasting glucose intolerance (FBG &gt;100mg/dL), fasting hyperinsulinemia (&gt;15µU/mL), or
             fasting insulin resistance (Homeostasis model for insulin resistance (HOMA) &gt;3.0). Any
             agents that might alter glucose metabolism (insulin, TZDs, metformin, glucocorticoids,
             sulfonylurea, corticosteroids, megace, rhGH, GH-secretagogue) during the 3 months
             prior to enrollment or at any time during enrollment. Volunteers with T2DM, IDDM or
             diabetic ketoacidosis will not be enrolled.

          4. History of serious CV disease or NYHA Functional Class III or IV, (e.g., recent MI,
             unstable angina, edema, CHF, CAD, CABG, valve disease (murmur), stroke, uncontrolled
             high blood pressure (resting &gt;160/95 mmHg), irregular heart rhythm, resting ST-segment
             depression &gt;1mm). Treatment with medications for a CV condition (cardiac glycosides α-
             or ß-blockers). Some antihypertensive medications (calcium-channel blocker, diuretic,
             angiotensin II receptor blockers (ARB), angiotensin converting enzyme inhibitors
             (ACE)) will be permitted.

          5. Moderate to severe renal insufficiency. Serum creatinine &gt;1.7 mg/dL (men) &gt;1.5 mg/dL
             (women).

          6. Known allergy or hypersensitivity to DPPIV-inhibitors.

          7. Plan to change anti-HIV medication regimen or prophylaxis for opportunistic infection
             within 6-months of starting study.Transitions among efavirenz-based regimens will be
             allowed (e.g., Efavirenz + lamivudine + zidovudine (combivir) to Efavirenz +
             emtricitabine + tenofovir (Atripla)).

          8. Lipid-lowering medications are permitted (fibrate or statin or niacin), but must be
             stable on that agent for at least 3 months prior to enrollment. Lipid-lowering agents
             cannot be started during the treatment period.

          9. Chronic hepatitis B infection (HB surface antigen positive). Active hepatitis C
             infection (detectable Hep C RNA). Those who have cleared hepatitis B or C infection
             are eligible.

         10. Hematocrit &lt;34% in men or &lt;25% in women with symptoms (fatigue, &quot;tired-legs&quot;,
             shortness of breath). Hemoglobin &lt;10 gm/100ml with symptoms.

         11. Nausea, vomiting, diarrhea (&gt;4 loose stools/day) that are unresponsive to treatment.
             History of eating disorder or significant GI-disease.

         12. Pregnant or nursing mothers. Women must agree to use an acceptable form of birth
             control during the study. If birth control pills are used, the woman must be stable on
             these medications for at least 6 months prior to enrollment.

         13. Active malignancy or treatment with chemotherapeutic agents or radiation therapy
             (within past 12 months).

         14. &gt;10% unintentional body weight loss during the 12 months prior to enrollment.

         15. &quot;Blinded&quot; investigational drugs/medications during the 3 months prior to enrollment
             that will not be unblinded before enrollment. Open-label investigational drugs are
             permitted (within past 3 months, no plan to stop during enrollment and not known to
             affect glucose, lipid, adipose tissue or liver metabolism).

         16. Over the counter agents that might alter glucose, lipid, or adipose tissue metabolism
             (e.g., creatine monohydrate, chromium picolinate, amino acid/protein supplements,
             medium- or long-chain fatty acids) within 1 month of enrollment. These supplements are
             not permitted during the treatment period.

         17. Reduced cognitive function/unable to provide voluntary informed consent. Prisoners are
             excluded.

         18. Active substance abuse that the physician-scientist believes may compromise safety,
             compliance, or interfere with study drug or data interpretation.

         19. Any cytokine or anti-cytokine therapy during 3 months prior to enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin E Yarasheski, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://diabetes.diabetesjournals.org/content/61/Supplement_1/A212.full.pdf+html?etoc</url>
    <description>Published abstract in Diabetes</description>
  </link>
  <results_reference>
    <citation>Goodwin SR, Reeds DN, Royal M, Struthers H, Laciny E, Yarasheski KE. Dipeptidyl Peptidase IV Inhibition Does Not Adversely Affect Immune and Virologic Status of HIV+ Men and Women. Diabetes. 2012;61(Suppl 1) A237 (abstract # 932-P).</citation>
  </results_reference>
  <results_reference>
    <citation>Goodwin SR, Reeds DN, Royal M, Struthers H, Laciny E, Yarasheski KE. Dipeptidyl peptidase IV inhibition does not adversely affect immune or virological status in HIV infected men and women: a pilot safety study. J Clin Endocrinol Metab. 2013 Feb;98(2):743-51. doi: 10.1210/jc.2012-3532. Epub 2012 Dec 21.</citation>
    <PMID>23264399</PMID>
  </results_reference>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2010</study_first_submitted>
  <study_first_submitted_qc>March 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2010</study_first_posted>
  <results_first_submitted>May 13, 2013</results_first_submitted>
  <results_first_submitted_qc>December 17, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 23, 2014</results_first_posted>
  <last_update_submitted>January 22, 2014</last_update_submitted>
  <last_update_submitted_qc>January 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Kevin Yarasheski, PhD</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>HIV-infected adults (18 – 65 years old) were recruited from the AIDS Clinical Trials Unit and the Infectious Diseases Clinic at Washington University School of Medicine. Thirty-one candidates were screened and 20 were enrolled; all participants were HIV positive but were otherwise healthy with stable immunologic and virologic status on HAART.</recruitment_details>
      <pre_assignment_details>Twenty participants were randomized to n=10 placebo or n=10 sitagliptin (Januvia(R)). Eleven volunteers were screened and found ineligible (see eligibility criteria), or did not choose to participate in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Four months of placebo to people living with HIV-1 who have well-controlled immunologic (CD4+ T-cell count &gt;350 cells/µL) and virologic (plasma HIV RNA &lt;50 copies/mL) status.
Placebo : Daily placebo for 4 months</description>
        </group>
        <group group_id="P2">
          <title>DPPIV Inhibition</title>
          <description>Four months of sitagliptin administration (100mg/d) to people living with HIV-1 who have well-controlled immunologic (CD4+ T-cell count &gt;350 cells/µL) and virologic (plasma HIV RNA &lt;50 copies/mL) status.
Sitagliptin : 100 mg sitagliptin daily for 4 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Four months of placebo to people living with HIV-1 who have well-controlled immunologic (CD4+ T-cell count &gt;350 cells/µL) and virologic (plasma HIV RNA &lt;50 copies/mL) status.
Placebo : Daily placebo for 4 months</description>
        </group>
        <group group_id="B2">
          <title>DPPIV Inhibition</title>
          <description>Four months of sitagliptin administration (100mg/d) to people living with HIV-1 who have well-controlled immunologic (CD4+ T-cell count &gt;350 cells/µL) and virologic (plasma HIV RNA &lt;50 copies/mL) status.
Sitagliptin : 100 mg sitagliptin daily for 4 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40" spread="15"/>
                    <measurement group_id="B2" value="36" spread="9"/>
                    <measurement group_id="B3" value="38" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>CD4+ T-cell Count</title>
        <time_frame>Monthly for 4 months</time_frame>
        <population>CD4+ T-cell count</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Four months of placebo to people living with HIV-1 who have well-controlled immunologic (CD4+ T-cell count &gt;350 cells/µL) and virologic (plasma HIV RNA &lt;50 copies/mL) status.
Placebo : Daily placebo for 4 months</description>
          </group>
          <group group_id="O2">
            <title>DPPIV Inhibition</title>
            <description>Four months of sitagliptin administration (100mg/d) to people living with HIV-1 who have well-controlled immunologic (CD4+ T-cell count &gt;350 cells/µL) and virologic (plasma HIV RNA &lt;50 copies/mL) status.
Sitagliptin : 100 mg sitagliptin daily for 4 months</description>
          </group>
        </group_list>
        <measure>
          <title>CD4+ T-cell Count</title>
          <population>CD4+ T-cell count</population>
          <units>cells/µL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="602" spread="91"/>
                    <measurement group_id="O2" value="648" spread="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="689" spread="153"/>
                    <measurement group_id="O2" value="750" spread="225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="696" spread="194"/>
                    <measurement group_id="O2" value="656" spread="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="686" spread="167"/>
                    <measurement group_id="O2" value="706" spread="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="681" spread="151"/>
                    <measurement group_id="O2" value="636" spread="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The main effect analysis was applied to both rows (timepoint) and categories (groups). It used linear mixed models to simultaneously assess differences in CD4+ T-cell count between the DPP4 inhibitor and placebo groups (categories) over time (rows). Pairwise post-hoc contrasts were performed to assess the between and within group differences in outcome measures at each time point.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>The a priori threshold for statistical significance was p&lt;0.05. The main effect analysis for CD4+ T-cell count over time and between the 2 groups did not achieve p&lt;0.05 (not statistically significant).</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Study subject was included in these models as a random variable to account for within-participant correlation.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma HIV Viremia (Viral Load)</title>
        <description>Percentage of participants with plasma HIV RNA copy number less than 48 copies/mL</description>
        <time_frame>Monthly for 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Four months of placebo to people living with HIV-1 who have well-controlled immunologic (CD4+ T-cell count &gt;350 cells/µL) and virologic (plasma HIV RNA &lt;50 copies/mL) status.
Placebo : Daily placebo for 4 months</description>
          </group>
          <group group_id="O2">
            <title>DPPIV Inhibition</title>
            <description>Four months of sitagliptin administration (100mg/d) to people living with HIV-1 who have well-controlled immunologic (CD4+ T-cell count &gt;350 cells/µL) and virologic (plasma HIV RNA &lt;50 copies/mL) status.
Sitagliptin : 100 mg sitagliptin daily for 4 months</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma HIV Viremia (Viral Load)</title>
          <description>Percentage of participants with plasma HIV RNA copy number less than 48 copies/mL</description>
          <units>percentage of participants below 48 c/mL</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The main effect analysis was applied to both rows (timepoint) and categories (groups). It used linear mixed models to simultaneously assess differences in plasma HIV RNA copy number/mL between the DPP4 inhibitor and placebo groups (categories) over time (rows). Pairwise post-hoc contrasts were performed to assess the between and within group differences in outcome measures at each time point.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>The a priori threshold for statistical significance was p&lt;0.05. The main effect analysis for plasma HIV RNA copy number/mL over time and between the 2 groups did not achieve p&lt;0.05 (not statistically significant).</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Soluble TNFR2; Serum Biomarkers of Immune Activation</title>
        <description>serum soluble tumor necrosis factor receptor-2 concentration</description>
        <time_frame>Baseline, week 8, week 16</time_frame>
        <population>sTNFR2</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Four months of placebo to people living with HIV-1 who have well-controlled immunologic (CD4+ T-cell count &gt;350 cells/µL) and virologic (plasma HIV RNA &lt;50 copies/mL) status.
Placebo : Daily placebo for 4 months</description>
          </group>
          <group group_id="O2">
            <title>DPPIV Inhibition</title>
            <description>Four months of sitagliptin administration (100mg/d) to people living with HIV-1 who have well-controlled immunologic (CD4+ T-cell count &gt;350 cells/µL) and virologic (plasma HIV RNA &lt;50 copies/mL) status.
Sitagliptin : 100 mg sitagliptin daily for 4 months</description>
          </group>
        </group_list>
        <measure>
          <title>Soluble TNFR2; Serum Biomarkers of Immune Activation</title>
          <description>serum soluble tumor necrosis factor receptor-2 concentration</description>
          <population>sTNFR2</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2220" spread="389"/>
                    <measurement group_id="O2" value="2436" spread="431"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2218" spread="411"/>
                    <measurement group_id="O2" value="2617" spread="638"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2279" spread="415"/>
                    <measurement group_id="O2" value="2388" spread="449"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The main effect analysis was applied to both rows (timepoint) and categories (groups). It used linear mixed models to simultaneously assess differences in serum TNFR2 levels between the DPP4 inhibitor and placebo groups (categories) over time (rows). Pairwise post-hoc contrasts were performed to assess the between and within group differences in outcome measures at each time point.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>The a priori threshold for statistical significance was p&lt;0.05. The main effect analysis for serum TNFR2 levels over time and between the 2 groups did not achieve p&lt;0.05 (not statistically significant).</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SDF1α; Serum Biomarkers of Immune Activation</title>
        <description>serum stromal cell-derived factor-1α concentration</description>
        <time_frame>Baseline, week 8, week 16</time_frame>
        <population>SDF1α</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Four months of placebo to people living with HIV-1 who have well-controlled immunologic (CD4+ T-cell count &gt;350 cells/µL) and virologic (plasma HIV RNA &lt;50 copies/mL) status.
Placebo : Daily placebo for 4 months</description>
          </group>
          <group group_id="O2">
            <title>DPPIV Inhibition</title>
            <description>Four months of sitagliptin administration (100mg/d) to people living with HIV-1 who have well-controlled immunologic (CD4+ T-cell count &gt;350 cells/µL) and virologic (plasma HIV RNA &lt;50 copies/mL) status.
Sitagliptin : 100 mg sitagliptin daily for 4 months</description>
          </group>
        </group_list>
        <measure>
          <title>SDF1α; Serum Biomarkers of Immune Activation</title>
          <description>serum stromal cell-derived factor-1α concentration</description>
          <population>SDF1α</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2327" spread="304"/>
                    <measurement group_id="O2" value="2378" spread="441"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2313" spread="364"/>
                    <measurement group_id="O2" value="1208" spread="605"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2309" spread="400"/>
                    <measurement group_id="O2" value="1277" spread="490"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The main effect analysis was applied to both rows (timepoint) and categories (groups). It used linear mixed models to simultaneously assess differences in serum SDF1α levels between the DPP4 inhibitor and placebo groups (categories) over time (rows). Pairwise post-hoc contrasts were performed to assess the between and within group differences in outcome measures at each time point.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0002</p_value>
            <p_value_desc>The a priori threshold for statistical significance was p&lt;0.05. The main effect analysis for SDF1-alpha levels over time and between the 2 groups achieved p&lt;0.0002.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>RANTES; Serum Biomarkers of Immune Activation</title>
        <description>serum Regulated on Activation, Normal T cell Expressed and Secreted concentration</description>
        <time_frame>Baseline, week 8, week 16</time_frame>
        <population>RANTES</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Four months of placebo to people living with HIV-1 who have well-controlled immunologic (CD4+ T-cell count &gt;350 cells/µL) and virologic (plasma HIV RNA &lt;50 copies/mL) status.
Placebo : Daily placebo for 4 months</description>
          </group>
          <group group_id="O2">
            <title>DPPIV Inhibition</title>
            <description>Four months of sitagliptin administration (100mg/d) to people living with HIV-1 who have well-controlled immunologic (CD4+ T-cell count &gt;350 cells/µL) and virologic (plasma HIV RNA &lt;50 copies/mL) status.
Sitagliptin : 100 mg sitagliptin daily for 4 months</description>
          </group>
        </group_list>
        <measure>
          <title>RANTES; Serum Biomarkers of Immune Activation</title>
          <description>serum Regulated on Activation, Normal T cell Expressed and Secreted concentration</description>
          <population>RANTES</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.8" spread="23.2"/>
                    <measurement group_id="O2" value="64.4" spread="37.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.3" spread="27.7"/>
                    <measurement group_id="O2" value="68.5" spread="43.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.9" spread="27.8"/>
                    <measurement group_id="O2" value="62.8" spread="32.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The main effect analysis was applied to both rows (timepoint) and categories (groups). It used linear mixed models to simultaneously assess differences in serum RANTES levels between the DPP4 inhibitor and placebo groups (categories) over time (rows). Pairwise post-hoc contrasts were performed to assess the between and within group differences in outcome measures at each time point.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>The a priori threshold for statistical significance was p&lt;0.05. The main effect analysis for serum RANTES levels over time and between the 2 groups did not achieve p&lt;0.05 (not statistically significant).</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oral Glucose Tolerance</title>
        <description>Area under the 75-gr oral glucose tolerance curve (AUCg) based on plasma glucose values measured at 0, 30, 60, 90, and 120 mins post-glucose challenge.</description>
        <time_frame>Baseline, week 8, week 16</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Four months of placebo to people living with HIV-1 who have well-controlled immunologic (CD4+ T-cell count &gt;350 cells/µL) and virologic (plasma HIV RNA &lt;50 copies/mL) status.
Placebo : Daily placebo for 4 months</description>
          </group>
          <group group_id="O2">
            <title>DPPIV Inhibition</title>
            <description>Four months of sitagliptin administration (100mg/d) to people living with HIV-1 who have well-controlled immunologic (CD4+ T-cell count &gt;350 cells/µL) and virologic (plasma HIV RNA &lt;50 copies/mL) status.
Sitagliptin : 100 mg sitagliptin daily for 4 months</description>
          </group>
        </group_list>
        <measure>
          <title>Oral Glucose Tolerance</title>
          <description>Area under the 75-gr oral glucose tolerance curve (AUCg) based on plasma glucose values measured at 0, 30, 60, 90, and 120 mins post-glucose challenge.</description>
          <units>mg*min/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline AUCg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142.5" spread="26.6"/>
                    <measurement group_id="O2" value="145.6" spread="32.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 AUCg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158.0" spread="26.7"/>
                    <measurement group_id="O2" value="133.6" spread="24.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 AUCg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157.5" spread="23.2"/>
                    <measurement group_id="O2" value="142.5" spread="21.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The main effect analysis was applied to both rows (timepoint) and categories (groups). It used linear mixed models to simultaneously assess differences in area under the glucose tolerance curves between the DPP4 inhibitor and placebo groups (categories) over time (rows). Pairwise post-hoc contrasts were performed to assess the between and within group differences in outcome measures at each time point.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.04</p_value>
            <p_value_desc>The a priori threshold for statistical significance was p&lt;0.05. The main effect analysis for area under the glucose tolerance curve over time and between the 2 groups achieved p&lt;0.04.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Self-reported Symptoms</title>
        <description>Cumulative number of self-reported symptoms based on the Division of AIDS Grading Scale for the Severity of Adult Adverse Events (0-4 scale where 0 is no new symptoms, 4 is serious adverse event or toxicity)</description>
        <time_frame>Monthly for 4 months</time_frame>
        <population>Cumulative frequency over 16 weeks of any self-reported symptoms on the DAIDS scale</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Four months of placebo to people living with HIV-1 who have well-controlled immunologic (CD4+ T-cell count &gt;350 cells/µL) and virologic (plasma HIV RNA &lt;50 copies/mL) status.
Placebo : Daily placebo for 4 months</description>
          </group>
          <group group_id="O2">
            <title>DPPIV Inhibition</title>
            <description>Four months of sitagliptin administration (100mg/d) to people living with HIV-1 who have well-controlled immunologic (CD4+ T-cell count &gt;350 cells/µL) and virologic (plasma HIV RNA &lt;50 copies/mL) status.
Sitagliptin : 100 mg sitagliptin daily for 4 months</description>
          </group>
        </group_list>
        <measure>
          <title>Self-reported Symptoms</title>
          <description>Cumulative number of self-reported symptoms based on the Division of AIDS Grading Scale for the Severity of Adult Adverse Events (0-4 scale where 0 is no new symptoms, 4 is serious adverse event or toxicity)</description>
          <population>Cumulative frequency over 16 weeks of any self-reported symptoms on the DAIDS scale</population>
          <units>total number of self reported symptoms</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hypoglycemia symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GI symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper respiratory symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Generalized fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other (e.g., rash, muscle pain, mood change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Kruskal-Wallis non-parametric test of cell frequencies</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>The a priori threshold for statistical significance was p&lt;0.05. The non-paramteric test for adverse event cummulative frequency between the 2 groups did not achieve p&lt;0.05 (not statistically significant)</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>16 weeks</time_frame>
      <desc>SAE or AE Any self reported symptom that was graded greater than 2 on the DAIDS severity scale during the 16 week period. These were reported as a serious or adverse event or toxicity.
Other adverse event: Any self-reported symptom that was graded less than or equal to 2 (DAIDS scale) during the 16 week period;these are not serious adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Four months of placebo to people living with HIV-1 who have well-controlled immunologic (CD4+ T-cell count &gt;350 cells/µL) and virologic (plasma HIV RNA &lt;50 copies/mL) status.
Placebo : Daily placebo for 4 months</description>
        </group>
        <group group_id="E2">
          <title>DPPIV Inhibition</title>
          <description>Four months of sitagliptin administration (100mg/d) to people living with HIV-1 who have well-controlled immunologic (CD4+ T-cell count &gt;350 cells/µL) and virologic (plasma HIV RNA &lt;50 copies/mL) status.
Sitagliptin : 100 mg sitagliptin daily for 4 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal symptoms</sub_title>
                <description>Not SAE; severity graded less than 2 on DAIDS</description>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Generalized fatigue</sub_title>
                <description>Not SAE; severity graded less than 2 on DAIDS</description>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Not SAE; severity graded less than 2 on DAIDS</description>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia symptoms</sub_title>
                <description>Not SAE; severity graded less than 2 on DAIDS</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle pain</sub_title>
                <description>Not SAE; severity graded less than 2 on DAIDS</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood change</sub_title>
                <description>Not SAE; severity graded less than 2 on DAIDS</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory symptoms</sub_title>
                <description>Not SAE; severity graded less than 2 on DAIDS</description>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <description>Not SAE; severity graded less than 2 on DAIDS</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Potential for type 2 error given small sample size. But, study was powered to detect significant decline in CD4 count. Measures of monocyte and lymphocyte activation should be conducted.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Kevin Yarasheski, PhD</name_or_title>
      <organization>Washington Univ Med Sch</organization>
      <phone>3143628173</phone>
      <email>key@wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

